|
HUE028588T2
(hu)
|
2005-12-13 |
2016-12-28 |
Incyte Holdings Corp |
Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
|
|
US7875636B2
(en)
*
|
2006-04-12 |
2011-01-25 |
Merck Sharp & Dohme Corp. |
Pyridyl amide T-type calcium channel antagonists
|
|
US7683060B2
(en)
*
|
2006-08-07 |
2010-03-23 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
GEP20125658B
(en)
*
|
2006-11-22 |
2012-10-10 |
Incyte Corp |
Imidazotriazines and imidazo pyrimidines as kinase inhibitors
|
|
EP2740731B1
(en)
|
2007-06-13 |
2016-03-23 |
Incyte Holdings Corporation |
Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
|
KR20100072266A
(ko)
*
|
2007-10-24 |
2010-06-30 |
머크 샤프 앤드 돔 코포레이션 |
헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제
|
|
PE20091468A1
(es)
|
2008-02-28 |
2009-10-22 |
Novartis Ag |
DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
|
|
SI2300455T1
(sl)
*
|
2008-05-21 |
2017-12-29 |
Incyte Holdings Corporation |
Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
|
|
WO2010002472A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Ambit Biosciences Corporation |
Jak kinase modulating compounds and methods of use thereof
|
|
FR2933982A1
(fr)
*
|
2008-07-18 |
2010-01-22 |
Sanofi Aventis |
Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
|
|
UY32049A
(es)
*
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
|
WO2010083283A2
(en)
|
2009-01-15 |
2010-07-22 |
Incyte Corporation |
Processes for preparing jak inhibitors and related intermediate compounds
|
|
US8957064B2
(en)
*
|
2009-02-13 |
2015-02-17 |
Bayer Intellectual Property Gmbh |
Fused pyrimidines
|
|
NZ596479A
(en)
|
2009-05-22 |
2014-01-31 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
BRPI1012108B8
(pt)
|
2009-05-22 |
2021-05-25 |
Incyte Corp |
composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
|
|
EP2448938B9
(en)
|
2009-06-29 |
2015-06-10 |
Incyte Corporation |
Pyrimidinones as pi3k inhibitors
|
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
|
IN2012DN01453A
(cg-RX-API-DMAC7.html)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
|
PT3511330T
(pt)
|
2009-12-31 |
2020-12-24 |
Hutchison Medipharma Ltd |
Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met
|
|
MX2012008898A
(es)
|
2010-02-03 |
2012-11-06 |
Incyte Corp |
Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
|
|
CA2792508C
(en)
|
2010-03-10 |
2018-01-16 |
Incyte Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
US8518945B2
(en)
*
|
2010-03-22 |
2013-08-27 |
Hoffmann-La Roche Inc. |
Pyrrolopyrazine kinase inhibitors
|
|
US8410117B2
(en)
*
|
2010-03-26 |
2013-04-02 |
Hoffmann-La Roche Inc. |
Imidazopyrimidine derivatives
|
|
KR20130094710A
(ko)
*
|
2010-04-14 |
2013-08-26 |
어레이 바이오파마 인크. |
Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
|
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
|
JP5960688B2
(ja)
|
2010-05-17 |
2016-08-02 |
インコゼン セラピューティクス プライベート リミテッド |
プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
|
|
EA202091303A3
(ru)
|
2010-05-21 |
2021-05-31 |
Инсайт Холдингс Корпорейшн |
Композиция ингибитора jak для местного применения
|
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
ES2536415T3
(es)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
|
|
JP5961187B2
(ja)
|
2010-12-20 |
2016-08-02 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
|
|
KR20140048079A
(ko)
|
2011-02-01 |
2014-04-23 |
교와 핫꼬 기린 가부시키가이샤 |
축환 복소환 유도체
|
|
US9108984B2
(en)
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
|
US8691807B2
(en)
|
2011-06-20 |
2014-04-08 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
MX389479B
(es)
|
2011-09-02 |
2025-03-20 |
Incyte Holdings Corp |
Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k)
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
|
CN103030654A
(zh)
*
|
2011-10-09 |
2013-04-10 |
济南赛文医药技术有限公司 |
一种小分子c-Met蛋白激酶抑制剂
|
|
SG11201401342VA
(en)
*
|
2011-10-12 |
2014-09-26 |
Array Biopharma Inc |
5,7-substituted-imidazo[1,2-c]pyrimidines
|
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
MX371119B
(es)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
|
|
CA2866321A1
(en)
|
2012-04-03 |
2013-10-10 |
Novartis Ag |
Tyrosine kinase inhibitor combinations and their use
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
CA2879704A1
(en)
*
|
2012-08-16 |
2014-02-20 |
Novartis Ag |
Combination of pi3k inhibitor and c-met inhibitor
|
|
KR102242077B1
(ko)
|
2012-11-15 |
2021-04-20 |
인사이트 홀딩스 코포레이션 |
룩솔리티니브의 서방성 제형
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
EP3489239B1
(en)
|
2013-03-06 |
2021-09-15 |
Incyte Holdings Corporation |
Processes and intermediates for making a jak inhibitor
|
|
CN105968115B
(zh)
*
|
2013-04-17 |
2018-11-09 |
上海医药集团股份有限公司 |
喹啉类化合物、其制备方法、中间体、药物组合物和应用
|
|
WO2014174478A1
(en)
|
2013-04-26 |
2014-10-30 |
Novartis Ag |
Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
|
|
MX376856B
(es)
|
2013-08-07 |
2025-03-07 |
Incyte Holdings Corp |
Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
GB201321732D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB201321736D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
WO2015123424A1
(en)
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
EP3392244A1
(en)
|
2014-02-13 |
2018-10-24 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
LT3105218T
(lt)
|
2014-02-13 |
2019-12-10 |
Incyte Corp |
Ciklopropilaminai kaip lsd1 inhibitoriai
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
BR112016022056B1
(pt)
|
2014-03-26 |
2023-04-11 |
Astex Therapeutics Limited |
Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
|
WO2016007736A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Imidazopyrazines as lsd1 inhibitors
|
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
|
WO2016007731A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Imidazopyridines and imidazopyrazines as lsd1 inhibitors
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
SG10201900648SA
(en)
*
|
2014-07-25 |
2019-02-27 |
Novartis Ag |
Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
|
|
WO2016011658A1
(en)
*
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
US10195208B2
(en)
*
|
2014-07-31 |
2019-02-05 |
Novartis Ag |
Combination therapy
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
CA2976790C
(en)
*
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI713497B
(zh)
*
|
2015-02-26 |
2020-12-21 |
南韓商愛思開生物製藥股份有限公司 |
咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
|
|
SG10201912302VA
(en)
|
2015-02-27 |
2020-02-27 |
Incyte Corp |
Salts of pi3k inhibitor and processes for their preparation
|
|
TWI706958B
(zh)
|
2015-03-10 |
2020-10-11 |
美商艾杜諾生物科技公司 |
活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
|
|
EA201792205A1
(ru)
|
2015-04-03 |
2018-02-28 |
Инсайт Корпорейшн |
Гетероциклические соединения как ингибиторы lsd1
|
|
CN106715440B
(zh)
|
2015-04-21 |
2019-02-22 |
江苏恒瑞医药股份有限公司 |
咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
|
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
|
MY195058A
(en)
|
2015-05-22 |
2023-01-05 |
Chong Kun Dang Pharmaceutical Corp |
Heterocyclicalkyl Derivative Compounds as Selective Histone Deacetylase Inhibitors and Pharmaceutical Compositions Comprising the Same
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
DK3334709T3
(da)
|
2015-08-12 |
2025-02-03 |
Incyte Holdings Corp |
Salte af en lsd1-hæmmer
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
CN108697794A
(zh)
*
|
2015-12-17 |
2018-10-23 |
诺华股份有限公司 |
C-met抑制剂和抗pd-1抗体分子的组合及其用途
|
|
BR112018015386A2
(pt)
|
2016-01-27 |
2019-03-19 |
Universität Zürich |
uso de moduladores de receptor gabaa para tratamento de prurido
|
|
TWI828027B
(zh)
*
|
2016-03-28 |
2024-01-01 |
美商英塞特公司 |
作為tam抑制劑之吡咯并三嗪化合物
|
|
CA3021678A1
(en)
|
2016-04-22 |
2017-10-26 |
Incyte Corporation |
Formulations of an lsd1 inhibitor
|
|
EP3464267B1
(en)
*
|
2016-05-23 |
2020-09-23 |
Boehringer Ingelheim International GmbH |
New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
CN106496000A
(zh)
*
|
2016-10-19 |
2017-03-15 |
蚌埠学院 |
一种3‑氟‑4‑溴‑苯乙酮的合成方法
|
|
WO2018119440A1
(en)
|
2016-12-22 |
2018-06-28 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
US10633387B2
(en)
|
2017-09-27 |
2020-04-28 |
Incyte Corporation |
Salts of TAM inhibitors
|
|
KR102775718B1
(ko)
*
|
2017-11-14 |
2025-03-06 |
칠드런'즈 메디컬 센터 코포레이션 |
인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
|
|
KR102740831B1
(ko)
|
2017-11-14 |
2024-12-11 |
칠드런'즈 메디컬 센터 코포레이션 |
신규 이미다조피리미딘 화합물 및 그의 용도
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
MD3746429T2
(ro)
|
2018-01-30 |
2022-08-31 |
Incyte Corp |
Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
|
|
US12528810B2
(en)
|
2018-03-01 |
2026-01-20 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Small molecule inhibitors of DYRK/CLK and uses thereof
|
|
KR20260080448A
(ko)
|
2018-03-30 |
2026-06-02 |
인사이트 코포레이션 |
Jak 억제제를 사용하는 화농성 한선염의 치료
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
CN110526916B
(zh)
*
|
2018-05-23 |
2021-07-13 |
海创药业股份有限公司 |
氘代Capmatinib化合物及其用途
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
IL278889B2
(en)
|
2018-06-01 |
2025-11-01 |
Incyte Corp |
Dosing regimen for the treatment of pi3k related disorders
|
|
CN108530337B
(zh)
*
|
2018-06-25 |
2020-11-03 |
南华大学 |
一种可选择性抑制胃癌细胞的吲哚酰胺类化合物
|
|
ES3031110T3
(en)
|
2018-06-29 |
2025-07-04 |
Incyte Corp |
Formulations of an axl/mer inhibitor
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
EP3856186A4
(en)
*
|
2018-09-28 |
2022-07-06 |
Arizona Board of Regents on behalf of the University of Arizona |
SMALL MOLECULAR DYRK1/CLK INHIBITORS AND USES THEREOF
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
JP7414827B2
(ja)
*
|
2018-12-20 |
2024-01-16 |
インサイト・コーポレイション |
アクチビン受容体様キナーゼ－２の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
|
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
WO2021173476A1
(en)
*
|
2020-02-24 |
2021-09-02 |
The Trustees Of Columbia University In The City Of New York |
Compounds, pharmaceutical formulations, and methods for treatment of cancer
|
|
PH12022552347A1
(en)
|
2020-03-06 |
2024-01-29 |
Incyte Corp |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
CN111825678A
(zh)
*
|
2020-06-05 |
2020-10-27 |
连庆泉 |
一种卡马替尼的制备方法
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
WO2022007752A1
(zh)
*
|
2020-07-06 |
2022-01-13 |
苏州晶云药物科技股份有限公司 |
苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
|
|
CN114621155A
(zh)
*
|
2020-12-14 |
2022-06-14 |
四川科伦药物研究院有限公司 |
一种制备卡马替尼的方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
US20240374571A1
(en)
|
2021-09-01 |
2024-11-14 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
CN113896732B
(zh)
*
|
2021-10-13 |
2023-09-12 |
沈阳红旗制药有限公司 |
抗癌药物卡马替尼的制备方法及其应用
|
|
WO2023249994A1
(en)
*
|
2022-06-22 |
2023-12-28 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
CA3261476A1
(en)
|
2022-07-08 |
2024-01-11 |
Astrazeneca Ab |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Combination with HGF Receptor Inhibitors for the Treatment of Cancer
|
|
CN116903627B
(zh)
*
|
2023-05-15 |
2024-01-16 |
云白药征武科技(上海)有限公司 |
一种咪唑并三嗪硫代苯甲酰胺衍生物及其制备方法和应用
|